9 March 2021 | 08:37am
StockMarketWire.com - UK stocks opened flat on Tuesday as investors weighed the benefits of easy fiscal and monetary policy with the inherent inflation risks, while companies continued to issue a mixed bag of earnings updates.
At 0823, the benchmark FTSE 100 index had edged up 1.27 points to 6,720.40.
Telecom group Vodafone fell 0.5% to 125.42p on setting a price range for the initial public offering of its Vantage Towers infrastructure business that would value it at between €11.4 billion and €14.7 billion.
The indicative price range was set at €22.50-to-€29.00 per share, with a base offer size of €2.0 billion, with flexibility to upsize €2.8 billion.
Immunotherapies Expose and Exploit Cancer s Varied Weaknesses genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Global Proteomics Partnering Terms and Agreements Analysis Report 2020
News provided by
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Proteomics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform
OXFORD, United Kingdom and SAN JOSE, Calif. and SHANGHAI, China, Jan. 19, 2021 WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, and Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate based therapies, today announced that OBT has selected a second bispecific program that will combine an anti-PD-L1 antibody with OBT’s immuno-oncology (IO) candidate, OX003. OBT will research and develop OX003/PD-L1, which employs WuXi Biologics’ proprietary bispecific antibody platform WuXiBody®.
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. Through this collaboration, OBT will validate five novel oncology drug targets, previously identified using OBTs OGAP discovery platform, and generate antibodies against these targets. Kite and Gilead will have the exclusive right to develop and commercialize therapies based on these targets or antibodies.